LSTA — Lisata Therapeutics Share News
0.000.00%
Last trade - 00:00- $30.60m
- $17.28m
- $0.17m
Lisata Therapeutics Inc expected to post a loss of 76 cents a share - Earnings Preview
Lisata Therapeutics Inc reports results for the quarter ended September 30 - Earnings Summary
Lisata Therapeutics Inc expected to post a loss of 75 cents a share - Earnings Preview
Brief: Lisata Therapeutics And Valo Therapeutics Announce Preclinical Research Collaboration
Lisata Therapeutics Inc expected to post a loss of 75 cents a share - Earnings Preview
Lisata Therapeutics Inc expected to post a loss of 77 cents a share - Earnings Preview
Brief: Lisata Therapeutics Announces Sponsored Preclinical Research Agreement With The University Of Cincinnati To Study Certepetide For The Treatment Of Endometriosis
U.S. STOCKS ON THE MOVE-MarketAxess, Perpetua Resources, Sotera Health
U.S. STOCKS ON THE MOVE-Modular Medical, Beazer Homes, oil firms
Lisata climbs on orphan drug status for bile duct cancer candidate
Lisata Therapeutics Inc reports results for the quarter ended in June - Earnings Summary
Lisata Therapeutics Inc expected to post a loss of 76 cents a share - Earnings Preview
Brief: Lisata Therapeutics Announces Completion of Enrollment in its Phase 2a BOLSTER Trial of Certepetide in First-Line Cholangiocarcinoma
Brief: Lisata Therapeutics Announces Full Enrollment Of Pancreatic Cancer Cohort Of Cendifox Trial
Brief: Lisata Therapeutics Receives Paediatric Investigation Plan Waiver From European Medicines Agency
Lisata Therapeutics Inc expected to post a loss of 72 cents a share - Earnings Preview
Lisata Therapeutics Inc expected to post a loss of 72 cents a share - Earnings Preview
Brief: Lisata Therapeutics Files For Mixed Shelf Offering Of Up To $150 Million - SEC Filing
Brief: Lisata Therapeutics' Cancer Drug Gets US FDA Orphan Drug Designation